Did We Nail It? Revisiting Our Top 6 Stock Predictions for 2026

Did We Nail It? Revisiting Our Top 6 Stock Predictions for 2026

Oil, small caps, biotech, AI, IPOs, prediction markets and the “there’s always a bull market somewhere” thesis are back on trial. In this episode, Lou Basenese and Dodd revisit The Big Skinny’s Top 6 Predictions for 2026 at the halfway mark to see what’s already working, what still needs time, and what investors should do next. From energy’s asymmetric setup and the small-cap earnings breakout to biotech’s next expansion phase, the AI power bottleneck, and the star-studded but doomed IPO class of 2026, Lou grades each call in plain English: nailed it, too early, or dead wrong. And this time, the audience gets a vote. Drop your score in the comments: which prediction will be the biggest winner by year-end — and which one is most at risk of blowing up? No fluff. No fear-mongering. Just a data-driven midyear checkup on where opportunity is emerging, where risk still lurks, and how to position for what comes next.

Every Breadth You Take: Why Mag 7 Lag Is Bullish For Stocks

Mag 7 lag, Meta’s AI cloud questions, biotech breakout signals, and the return of broader market leadership — that’s the point of this episode of The Big Skinny. Lou Basenese explains why investors shouldn’t bemoan the fact that the Mag 7 are lagging. They should embrace it. Why? Because a healthy bull market eventually broadens beyond a handful of mega-cap winners, and that’s exactly what appears to be happening now. Lou breaks down why not every mega-cap tech stock deserves your money right now and where the bigger profit opportunities reside as earnings growth and market breadth improve. Then Barron’s Josh Schafer joins to dig into Meta’s AI cloud ambitions, the risks behind selling “excess compute,” and why Progress Software (PRGS) may be a smarter AI-adjacent opportunity than investors realize. No fluff. No Mag 7 panic. Just a sharper look at why this bull market may be stronger because leadership is broadening.

Buy Every Chip Stock Dip: The AI Top Isn’t Close

Chip bubble calls, AI demand denial, semiconductor selloffs, prediction market hype, and the tippy-top trap. Lou Basenese takes on the insane idea that we’re already near the end of the AI chip cycle – when the world has never seen a technology demand curve like this before. In this episode, Lou breaks down why AI chip demand is still early, why every serious semi dip deserves attention, and why iShares Semiconductor ETF (SOXX) remains the simplest way to stay exposed without overthinking it and over-investing in Nvidia (NVDA) or Micron (MU). Plus, Lou revisits his raw and personal conversation with Louis Ruggiero and the data behind Phil Rosen of ProCap Financial’s conviction the current bull market might have years left to run. He wraps it all up with Dodd and rapid-fire takes on SoftBank’s AI conviction, Big Tech’s AI spending, productivity gains, semiconductor earnings strength, and the next great speculative temptation.

ETFs Gone Wild: How to Find the Few Worth Owning

Too many ETF tickers, too little time. There are officially more ETFs than publicly traded stocks in the U.S., and no normal investor has the time — or the stomach — to sort through thousands of products that all claim to be the answer. That’s the setup for this episode of The Big Skinny. Lou Basenese asks the question everyday investors should be asking: if there’s now an ETF for everything, how do you find the ones actually worth owning? He starts with the big picture — why the ETF boom has gone from useful to absurd, why so many funds are too small to matter, and how to separate real opportunity from ticker clutter. Then, he’s joined by longtime friends and market pros Keith Fitz-Gerald and David Nicholas to spotlight one fund Lou believes cuts through the chaos: the Fitz-Gerald Must Have Portfolio ETF (FITZ). From there, Lou shares insights from his latest interview with Matthew Tuttle of Tuttle Capital Management who says “99% of ETFs suck.” Then Lou and his trusted partner Dodd dish on GLP-1 momentum, Andrew Left’s fraud conviction, what Cushing oil inventories are really signaling, the longevity fundraising boom, and the kind of IPO price-to-sales math that should make investors squirm.

Biotech Breakthroughs, GPUs & the Great SpaceX IPO Temptation

GLP-1s are the first line of biotech innovations that are remaking medicine, GPUs are still fueling the AI boom, and the coming SpaceX IPO is about to test investors’ impulse control. That (and more) is the focus of this episode of The Big Skinny. Lou Basenese makes the case that the next trillion-dollar growth trend after AI might be longevity — and that Eli Lilly (LLY) represents the smartest way to play the impending mega boom. Think chronic disease, cardiovascular care, and maybe even the road to living to 150 years. Then Barron's Josh Schafer joins to explain why interest rate volatility may matter less than people think, and why the real macro question is whether anything can stop the AI capex machine. Later, Gene Mack, CEO of Gain Therapeutics, adds a biotech operator’s perspective from the front lines of the longevity and neuroscience race. And yes, Lou also gets into the SpaceX IPO. Specifically why investors should think twice before falling for Musk Mania and chasing an IPO built on hype, premium pricing, and a whole lot of wishful thinking. No fluff. No fear-mongering. Just a sharper, funnier, and profitable look at where the real growth may be hiding.